Jean-François Morin

Elkedonia is a pioneering start-up company committed to transforming the treatment of mental health disorders. Our mission is to develop a new generation of antidepressants that are fast-acting, highly effective, and safe. Our breakthrough approach is based on first-in-class neuroplastogens, which promote neuroplasticity without the side effects of psychedelics and ketamine. By eliminating risks of dependence, sedation, or psychotic effects, our innovative treatments empower patients to rediscover the joys of life while significantly reducing the risk of relapse and suicide. At Elkedonia, we believe in a future where mental health treatments enhance well-being without compromise. Join us in this therapeutic revolution. 🧠 Innovating for better mental health.

May Health, formerly AblaCare, is developing a modern approach to PCOS.

Pixee Medical is developing a new generation of computer assisted surgery tools using augmented reality and mixed reality. A simple pair of smart glasses allows the navigation of prostheses without percutaneous bone reference, nor associated consumable. Our dedicated instrumentation automatically transfers essential anatomical landmarks to the software. The surgical parameters are then displayed on a virtual screen combining real and virtual images. To do this, our company has developed proprietary software tools to use the simple camera from glasses to accurately locate bone structures and instruments. Our customizable workflows provide the surgeon with assistance tailored to their needs without wasting time. Our products are affordable and without disposable.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. We are currently advancing a pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions. Our lead product candidate, apraglutide, is a second generation, potentially best-in-class, synthetic peptide analog of glucagon-like peptide-2, or GLP-2, that is being evaluated in two Phase 2 clinical trials for the treatment of patients with short bowel syndrome, or SBS, a malabsorption disorder caused by the loss of functional small intestine. Our second product candidate, TA-46, has completed a Phase 1 clinical trial and is designed to address the root molecular cause of achondroplasia, a rare genetic condition and the most common form of short-limbed dwarfism in humans. View our social media community guidelines here: http://bit.ly/2TdB4Vm.

Transforming Rare Disease Treatment At Orphalan we identify, develop, and provide access to innovative treatments for patients with rare diseases to make a positive and meaningful difference.

At gmp-orphan (GMPO), it is our mission to identify, develop and provide access to innovative treatments to patients with rare diseases. Our experienced pharmaceutical development and commercial team in the field of rare diseases is critical in advancing this mission. gmp-orphan (GMPO) was founded in 2011 and the company’s most advanced product candidate is Cuprior for the treatment of Wilson Disease.

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).

Elkedonia is a pioneering start-up company committed to transforming the treatment of mental health disorders. Our mission is to develop a new generation of antidepressants that are fast-acting, highly effective, and safe. Our breakthrough approach is based on first-in-class neuroplastogens, which promote neuroplasticity without the side effects of psychedelics and ketamine. By eliminating risks of dependence, sedation, or psychotic effects, our innovative treatments empower patients to rediscover the joys of life while significantly reducing the risk of relapse and suicide. At Elkedonia, we believe in a future where mental health treatments enhance well-being without compromise. Join us in this therapeutic revolution. 🧠 Innovating for better mental health.

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.

May Health, formerly AblaCare, is developing a modern approach to PCOS.

Pixee Medical is developing a new generation of computer assisted surgery tools using augmented reality and mixed reality. A simple pair of smart glasses allows the navigation of prostheses without percutaneous bone reference, nor associated consumable. Our dedicated instrumentation automatically transfers essential anatomical landmarks to the software. The surgical parameters are then displayed on a virtual screen combining real and virtual images. To do this, our company has developed proprietary software tools to use the simple camera from glasses to accurately locate bone structures and instruments. Our customizable workflows provide the surgeon with assistance tailored to their needs without wasting time. Our products are affordable and without disposable.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.